The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A)

被引:65
作者
Clarkson, KS [1 ]
Sturdgess, IC [1 ]
Molyneux, AJ [1 ]
机构
[1] Northampton Gen Hosp, Dept Cellular Pathol, Northampton NN1 5BD, England
关键词
T311 (anti-tyrosinase); A103 (anti melan-A); immunohistochemistry; melanocytic lesions;
D O I
10.1136/jcp.54.3.196
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim-To compare the sensitivity and staining pattern of the new immunohistochemical antibody to tyrosinase (T311) with S-100, HMB45, and the recently evaluated antibody to melan-A (A103) in a range of melanocytic lesions. Method-Archival, formalin fixed, paraffin wax embedded sections from 50 benign and malignant melanocytic lesions were stained immunohistochemically with anti-tyrosinase, A103, S-100, and HMB45. They were scored semiquantitatively for the distribution and intensity of staining. Results-All melanomas, with the exception of desmoplastic melanoma, showed some staining with all four antibodies. Overall, T311 and A103 showed an intermediate sensitivity compared with that of S-100 and HMB45. T311 stained most benign and malignant lesions strongly and diffusely with minimal background staining. Immunoreactivity was found to be patchy in some naevi, with weak or absent staining of the mature melanocytes. A103 showed strong and diffuse staining of all benign lesions and most melanomas with minimal background staining. S-100 was the most sensitive, with diffuse staining of most lesions, including desmoplastic and metastatic melanoma, but lacked specificity. HMB45 was the least sensitive antibody, frequently demonstrating patchy staining with absent staining in some benign naevi. Conclusions-S-100 remains the most sensitive marker of melanocytes. However, because of its lack of specificity, it should be used with at feast one other more specific antibody. HMB45 is more specific, but lacks sensitivity; T311 is a reliable marker of melanocytes in paraffin wax embedded sections and is worth consideration for use in a staining panel, although it shows no additional benefit over A103.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 27 条
[21]   Molecular staging of malignant melanoma - Correlation with clinical outcome [J].
Shivers, SC ;
Wang, XN ;
Li, WG ;
Joseph, E ;
Messina, J ;
Glass, LF ;
DeConti, R ;
Cruse, CW ;
Berman, C ;
Fenske, NA ;
Lyman, GH ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (16) :1410-1415
[22]   HMB-45 STAINING IN BENIGN AND MALIGNANT MELANOCYTIC LESIONS - A REFLECTION OF CELLULAR ACTIVATION [J].
SKELTON, HG ;
SMITH, KJ ;
BARRETT, TL ;
LUPTON, GP ;
GRAHAM, JH .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1991, 13 (06) :543-550
[23]   HMB-45 RECOGNIZES STIMULATED MELANOCYTES [J].
SMOLLER, BR ;
MCNUTT, NS ;
HSU, A .
JOURNAL OF CUTANEOUS PATHOLOGY, 1989, 16 (02) :49-53
[24]  
Stevens GL, 1996, CANCER EPIDEM BIOMAR, V5, P293
[25]   IMMUNOHISTOCHEMICAL STUDY ON THE DISTRIBUTION OF ALPHA-SUBUNITS AND BETA-SUBUNITS OF S-100 PROTEIN IN HUMAN NEOPLASM AND NORMAL-TISSUES [J].
TAKAHASHI, K ;
ISOBE, T ;
OHTSUKI, Y ;
AKAGI, T ;
SONOBE, H ;
OKUYAMA, T .
VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1984, 45 (04) :385-396
[26]   NEW SITES OF HUMAN S-100 IMMUNOREACTIVITY DETECTED WITH MONOCLONAL-ANTIBODIES [J].
VANSTAPEL, MJ ;
GATTER, KC ;
DEWOLFPEETERS, C ;
MASON, DY ;
DESMET, VD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 85 (02) :160-168
[27]  
1998, BANDOLIER, V47, P7